Addback of Donor CD45RA Depleted Cells
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
What will happen during the trial?
The risk of severe graft versus host disease (GVHD) is increased with the use of unrelated and partially matched related donors. T cell depletion reduces the risk of severe GVHD, but immune reconstitution is delayed. Important memory T cells that may protect patients from fungal and viral infections are also removed in the T depletion process. CD45RA depletion has been studied both as a single step to reduce the risk of GVHD, and also, in conjunction with αβTCR depleted hematopoietic stem cell grafts to accelerate immune reconstitution. This is a single institutional pilot trial of this T cell depletion technique. Patients with acute leukemias at high risk for relapse are eligible to participate. Patients will be given CD45RA depleted donor peripheral stem cells (PSCs) following T depleted hematopoietic stem cell transplant (HSCT). A short course of GVHD prophylaxis will be used after CD45RA depletion.
More Information
- Trial Status
- Accepting patients
- Enrollment
- 50 patients (estimated)
- Sponsors
- Children's Hospital of Philadelphia
- Tags
- Donor Lymphocyte Infusion (DLI), Chemotherapy, Allogeneic Stem Cell Transplant, T Cell, Post-Allogeneic Stem Cell Transplant, Radiation Therapy
- Trial Type
- Supportive
- Last Update
- SparkCures ID
- 1653
- NCT Identifier
- NCT03810196
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.